Pre-made Odronextamab benchmark antibody ( Bispecific mAb, anti-MS4A1/CD20;CD3E therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-391

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-391 Category Tags ,

Product Details

Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibody

INN Name

Odronextamab

Target

MS4A1,CD3E

Format

Bispecific mAb

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa,Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2019

Companies

Regeneron Pharmaceuticals

Conditions Approved

NA

Conditions Active

Follicular lymphoma,B-cell lymphoma,Chronic lymphocytic leukaemia,Non-Hodgkin's lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

MS4A1,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide